The HS1BP3 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the HS1BP3 gene in HeLa cells. This product provides a heterogeneous pool of edited cells, enabling loss-of-function studies of HS1BP3 without clonal selection. The target gene disruption is achieved through CRISPR/Cas9-mediated genome editing, resulting in a polyclonal knockout model suitable for investigating the molecular functions of the encoded adapter protein within a well-characterized human epithelial cell context. Researchers can utilize these polyclonal knockout cells to dissect HS1BP3 involvement in actin cytoskeleton dynamics, cell adhesion, and migration, bypassing the variability inherent in single-cell-derived clones.
HeLa cells, the parental line for this knockout model, are an immortalized human cervical adenocarcinoma epithelial cell line originally derived in 1951 from a biopsy of Henrietta Lacks. These cells are widely employed in biomedical research as a robust model for epithelial biology, cancer biology, and signal transduction studies. Their epithelial origin and transformed phenotype make them particularly relevant for investigating mechanisms of tumor cell adhesion and invasion. The well-documented genetic and phenotypic characteristics of HeLa cells provide a reliable platform for studying the functional consequences of HS1BP3 gene disruption in a cervical cancer background.
HS1BP3 encodes an adapter protein that directly interacts with hematopoietic lineage cell-specific protein 1 (HS1/HCLS1), 14-3-3 proteins, and actin. This molecular interaction network links immune receptor signals to actin cytoskeleton reorganization. HS1BP3 functions downstream of T cell receptor (TCR) and B cell receptor activation, as well as integrin engagement, with upstream kinases such as SYK and ZAP70 phosphorylating HS1 to facilitate complex formation. The HS1BP3-HS1 complex modulates downstream effectors including RAC1, CDC42, and the Arp2/3 complex, thereby regulating actin polymerization, focal adhesion turnover, and cell migration. Thus, HS1BP3 serves as a critical node connecting surface receptor signaling to cytoskeletal remodeling.
In the HeLa cell context, disruption of HS1BP3 expression offers a model to dissect how this adapter protein contributes to epithelial cancer cell adhesion and motility. HeLa cells endogenously express components of integrin and actin regulatory pathways, making them suitable for examining HS1BP3-dependent modulation of migration and focal adhesion dynamics. This knockout system is directly relevant to research on cancer metastasis, where dysregulation of cell adhesion and cytoskeletal reorganization promotes invasion. Additionally, given the association of HS1BP3 with essential tremor, these cells provide a complementary in vitro tool to explore molecular links between HS1BP3 function and neuronal or non-neuronal mechanisms underlying this movement disorder.
Researchers can apply the HS1BP3 Knockout HeLa Polyclonal Cells in diverse experimental workflows. Functional assays such as transwell migration and wound healing assays enable quantitative assessment of cell motility and invasion properties. Immunofluorescence staining for actin filaments and focal adhesion markers permits visualization of cytoskeletal architecture, while co-immunoprecipitation and western blotting facilitate analysis of HS1BP3 protein interactions and signaling complexes. Transcriptional profiling by RT-qPCR allows monitoring of pathway activity, and cell adhesion assays directly measure attachment strength. These polyclonal knockout cells are ideal for screening putative HS1BP3 interactors or evaluating the role of HS1BP3 in integrin- and TCR-like signaling cascades. For further information, please contact Ascent Research.
